Compile Data Set for Download or QSAR
Report error Found 305 Enz. Inhib. hit(s) with Target = 'Cyclin-dependent kinase 5 activator 1 [99-307]'
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.800nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM525738(US11174252, Compound 33)
Affinity DataIC50: 1nMAssay Description:CDK5 (p25): IC50 values of compounds against CDK5 (p25) were determined by Z′-LYTE™. These screening assays were performed at Invitrogen L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 1.30nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM525743(US11174252, Compound 38)
Affinity DataIC50: 2nMAssay Description:CDK5 (p25): IC50 values of compounds against CDK5 (p25) were determined by Z′-LYTE™. These screening assays were performed at Invitrogen L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20870(3-{2-[(thiophene-2-sulfonyl)methyl]-1,3-thiazol-4-...)
Affinity DataIC50: 2.10nMT: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20851(7-(piperidin-1-ylcarbonyl)-3-[2-(pyridin-4-yl)-1,3...)
Affinity DataIC50: 2.70nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM525729(US11174252, Compound 24)
Affinity DataIC50: 3.5nMAssay Description:CDK5 (p25): IC50 values of compounds against CDK5 (p25) were determined by Z′-LYTE™. These screening assays were performed at Invitrogen L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM525730(US11174252, Compound 25)
Affinity DataIC50: 3.60nMAssay Description:CDK5 (p25): IC50 values of compounds against CDK5 (p25) were determined by Z′-LYTE™. These screening assays were performed at Invitrogen L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20856(4-amino-6-chloro-3-[2-(pyridin-4-yl)-1,3-thiazol-4...)
Affinity DataIC50: 3.80nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20850(7-[(4-methylpiperazin-1-yl)carbonyl]-3-[2-(pyridin...)
Affinity DataIC50: 4.40nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20848(3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-7-(trifluoro...)
Affinity DataIC50: 6.30nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM525750(US11174252, Compound 437)
Affinity DataIC50: 7.70nMAssay Description:CDK5 (p25): IC50 values of compounds against CDK5 (p25) were determined by Z′-LYTE™. These screening assays were performed at Invitrogen L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20849(N-[2-(dimethylamino)ethyl]-N-ethyl-2-oxo-3-[2-(pyr...)
Affinity DataIC50: 8.30nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20869(3-{2-[(pyridine-2-sulfonyl)methyl]-1,3-thiazol-4-y...)
Affinity DataIC50: 10nMT: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20847(6-chloro-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2...)
Affinity DataIC50: 11nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20855(4-amino-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2-...)
Affinity DataIC50: 11nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 14nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20832(7-fluoro-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2...)
Affinity DataIC50: 16nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601938(US11643416, Compound 18 | (R)-4-((6'-(fluoromethyl...)
Affinity DataIC50: 17nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7492(3-[(2Z,3E)-3-(hydroxyimino)-2,3-dihydro-1H-indol-2...)
Affinity DataIC50: 20nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7264(NSC 709125 | 4,5-dimethoxy-14-nitro-8,18-diazatetr...)
Affinity DataIC50: 21nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20866(3-[2-(4-hydroxyphenyl)-1,3-thiazol-4-yl]-1,2-dihyd...)
Affinity DataIC50: 24nMT: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM525755(US11174252, Compound 442)
Affinity DataIC50: 27nMAssay Description:CDK5 (p25): IC50 values of compounds against CDK5 (p25) were determined by Z′-LYTE™. These screening assays were performed at Invitrogen L...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7491(4-[2-Amino-5-oxo-1,5-dihydro-imidazol-(4Z)-ylidene...)
Affinity DataIC50: 28nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20868(3-{2-[(benzenesulfonyl)methyl]-1,3-thiazol-4-yl}-1...)
Affinity DataIC50: 29nMT: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7269(CHEMBL121492 | 3-[9-oxo-14-(trifluoromethyl)-8,18-...)
Affinity DataIC50: 33nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20843(methyl 2-oxo-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]...)
Affinity DataIC50: 33nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20833(7-bromo-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2,...)
Affinity DataIC50: 38nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM525749(US11174252, Compound 436)
Affinity DataIC50: 38nMAssay Description:CDK5 (p25): IC50 values of compounds against CDK5 (p25) were determined by Z′-LYTE™. These screening assays were performed at Invitrogen L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7262(NSC 705701 | BDBM84528 | alsterpaullone | 9-Nitrop...)
Affinity DataIC50: 40nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7263(CHEMBL299756 | 9-oxo-8,18-diazatetracyclo[9.7.0.0^...)
Affinity DataIC50: 44nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20861(3-[2-(pyridin-3-yl)-1,3-thiazol-4-yl]-1,2-dihydroq...)
Affinity DataIC50: 50nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20842(3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2-dihydroq...)
Affinity DataIC50: 54nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7265(NSC 708244 | 4,5-dimethoxy-9-oxo-8,18-diazatetracy...)
Affinity DataIC50: 60nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7424((2 Z,3 E)-5,6-Dichloroindirubin-3 -oxime | 6,5-dic...)
Affinity DataIC50: 60nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM27218((2R)-2-({4-[(3-chlorophenyl)amino]-8-(propan-2-yl)...)
Affinity DataIC50: 60nMpH: 7.5 T: 2°CAssay Description:In vitro kinase assay using purified enzyme, was incubated at 30 °C with substrate, and test compounds in the presence of 15 uM ATP/ [gamma-33P]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20838(7-(morpholin-4-ylmethyl)-3-[2-(pyridin-4-yl)-1,3-t...)
Affinity DataIC50: 62nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601939(US11643416, Compound 19 | (S)-4-((6'-methyl-8'-oxo...)
Affinity DataIC50: 62nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7330(NSC 720310 | 4-methoxy-14-nitro-8,18-diazatetracyc...)
Affinity DataIC50: 70nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM27217(GP0210 | (2R)-2-{[4-(benzylamino)-8-(propan-2-yl)p...)
Affinity DataIC50: 70nMpH: 7.5 T: 2°CAssay Description:In vitro kinase assay using purified enzyme, was incubated at 30 °C with substrate, and test compounds in the presence of 15 uM ATP/ [gamma-33P]...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20830(6-fluoro-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2...)
Affinity DataIC50: 72nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM27216((2R)-2-({6-[(3-chlorophenyl)amino]-9-(propan-2-yl)...)
Affinity DataIC50: 75nMpH: 7.5 T: 2°CAssay Description:In vitro kinase assay using purified enzyme, was incubated at 30 °C with substrate, and test compounds in the presence of 15 uM ATP/ [gamma-33P]...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20820(3-[4-(pyridin-4-yl)-1,3-thiazol-2-yl]-1,2,3,4-tetr...)
Affinity DataIC50: 77nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20819(3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2,3,4-tetr...)
Affinity DataIC50: 79nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7401(6-bromoindirubin-3 -oxime | (3E)-6-bromo-3-[3-(hyd...)
Affinity DataIC50: 83nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7393(Indirubin-3 -monoxime | 3-[(2Z,3E)-3-(hydroxyimino...)
Affinity DataIC50: 100nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7407(6-chloro-3-[(2Z,3E)-3-(hydroxyimino)-2,3-dihydro-1...)
Affinity DataIC50: 100nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7425((2 Z,3 E)-5,6-Dichloroindirubin-3 -acetoxime | [(3...)
Affinity DataIC50: 100nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7340(13-nitro-3-thia-7,17-diazatetracyclo[8.7.0.0^{2,6}...)
Affinity DataIC50: 100nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM20846(6-fluoro-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2...)
Affinity DataIC50: 110nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
Displayed 1 to 50 (of 305 total ) | Next | Last >>
Jump to: